Sotera Health upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Matthew Sykes upgraded Sotera Health (SHC) to Buy from Neutral with a price target of $17, up from $14, representing 36% upside. The company’s “durable” business model with exposure to commercial pharmaceutical and medical devices has become “much more attractive” in the current environment given increased macro-related uncertainty, the analyst tells investors in a research note. The firm says Sotera is also well positioned in the tariff-related uncertainty, given its service based model in its Sterigenics and Nelson Labs businesses and the exemption of Nelson Cobalt related products from tariffs according to the U.S. annex.